The currently existing models and techniques provide insufficient certainties in the assessment of the harmfulness of nanoparticles and nanomaterials to people and the environment.

RIVM contributes to the safe use of nanomaterials through research, alerts and policy consultations, and this work is demonstrated in a short informative film.

RIVM will be working alongside a consortium of 23 international partners on a safe design for ‘new’ nanoparticles.

Nanotechnology offers improved options for the diagnosis and treatment of cancer.

Routine screening for anorectal chlamydia among HIV-positive men who have sex with men (MSM) could avert further spread of chlamydia and HIV in the total MSM population.

Until 2003, Lymphogranuloma venereum (LGV), an aggressive form of chlamydia, was considered to be a rare tropical disease, endemic to Africa, Asia and the Caribbean.

In 2012, the number of new consultations at Sexually Transmitted Infections (STI) clinics in the Netherlands increased by 7% over the previous year.

In a new publication, RIVM indicates scientific challenges in the use of the EU definition for nanomaterial in legislation.

In recent years, an increasing number of applications and products containing or using nanomaterials have become available.